Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that rece...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of autoimmunity 2020-11, Vol.114, p.102512-102512, Article 102512
Hauptverfasser:	Morrison, Austin R., Johnson, Joseph M., Griebe, Kristin M., Jones, Mathew C., Stine, John J., Hencken, Laura N., To, Long, Bianchini, Monica L., Vahia, Amit T., Swiderek, Jennifer, Ramesh, Mayur S., Peters, Michael A., Smith, Zachary R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Betacoronavirus - immunology C-Reactive Protein - analysis Coronavirus Infections - blood Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - mortality COVID-19 Critical illness Cytokine release syndrome Cytokine Release Syndrome - blood Cytokine Release Syndrome - drug therapy Cytokine Release Syndrome - immunology Cytokine Release Syndrome - mortality Female Hospital Mortality Humans Infusions, Intravenous Interleukin-6 Interleukin-6 - immunology Interleukin-6 - metabolism Male Michigan - epidemiology Middle Aged Organ Dysfunction Scores Pandemics Pneumonia, Viral - blood Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - mortality Prognosis Receptors, Interleukin-6 - antagonists & inhibitors Receptors, Interleukin-6 - metabolism Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Survival Analysis Time Factors Time-to-Treatment Tocilizumab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!